vs

Side-by-side financial comparison of Ascendis Pharma A/S (ASND) and Shutterstock, Inc. (SSTK). Click either name above to swap in a different company.

Ascendis Pharma A/S is the larger business by last-quarter revenue ($267.3M vs $220.2M, roughly 1.2× Shutterstock, Inc.). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs -12.0%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs 1.4%).

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

Shutterstock, Inc. is an American provider of stock photography, stock footage, stock music, and editing tools; it is headquartered in New York. Founded in 2002 by programmer and photographer Jon Oringer, Shutterstock maintains a library of around 200 million royalty-free stock photos, vector graphics, and illustrations, with around 10 million video clips and music tracks available for licensing. Originally a subscription site only, Shutterstock expanded beyond subscriptions into à la carte p...

ASND vs SSTK — Head-to-Head

Bigger by revenue
ASND
ASND
1.2× larger
ASND
$267.3M
$220.2M
SSTK
Growing faster (revenue YoY)
ASND
ASND
+54.3% gap
ASND
42.3%
-12.0%
SSTK
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
1.4%
SSTK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASND
ASND
SSTK
SSTK
Revenue
$267.3M
$220.2M
Net Profit
$-16.0M
Gross Margin
90.5%
55.8%
Operating Margin
-1.1%
Net Margin
-7.3%
Revenue YoY
42.3%
-12.0%
Net Profit YoY
-1021.0%
EPS (diluted)
$-0.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASND
ASND
SSTK
SSTK
Q4 25
$267.3M
$220.2M
Q3 25
$230.7M
$260.1M
Q2 25
$170.7M
$267.0M
Q1 25
$109.0M
$242.6M
Q4 24
$187.8M
$250.3M
Q3 24
$62.5M
$250.6M
Q2 24
$38.9M
$220.1M
Q1 24
$103.6M
$214.3M
Net Profit
ASND
ASND
SSTK
SSTK
Q4 25
$-16.0M
Q3 25
$-65.9M
$13.4M
Q2 25
$-42.0M
$29.4M
Q1 25
$-102.2M
$18.7M
Q4 24
$-1.4M
Q3 24
$-107.1M
$17.6M
Q2 24
$-118.1M
$3.6M
Q1 24
$-141.5M
$16.1M
Gross Margin
ASND
ASND
SSTK
SSTK
Q4 25
90.5%
55.8%
Q3 25
89.5%
60.6%
Q2 25
80.1%
60.3%
Q1 25
82.6%
58.4%
Q4 24
91.9%
55.1%
Q3 24
80.6%
58.3%
Q2 24
68.2%
58.5%
Q1 24
92.1%
58.8%
Operating Margin
ASND
ASND
SSTK
SSTK
Q4 25
-1.1%
Q3 25
5.1%
12.5%
Q2 25
-33.5%
13.0%
Q1 25
-103.2%
4.2%
Q4 24
5.3%
Q3 24
-167.3%
7.2%
Q2 24
-370.2%
9.4%
Q1 24
-51.2%
7.8%
Net Margin
ASND
ASND
SSTK
SSTK
Q4 25
-7.3%
Q3 25
-28.5%
5.1%
Q2 25
-24.6%
11.0%
Q1 25
-93.7%
7.7%
Q4 24
-0.6%
Q3 24
-171.5%
7.0%
Q2 24
-303.9%
1.6%
Q1 24
-136.6%
7.5%
EPS (diluted)
ASND
ASND
SSTK
SSTK
Q4 25
$-0.47
Q3 25
$0.37
Q2 25
$0.82
Q1 25
$0.53
Q4 24
$-0.04
Q3 24
$0.50
Q2 24
$0.10
Q1 24
$0.45

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASND
ASND
SSTK
SSTK
Cash + ST InvestmentsLiquidity on hand
$665.3M
$178.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$-175.8M
$581.0M
Total Assets
$1.4B
$1.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASND
ASND
SSTK
SSTK
Q4 25
$665.3M
$178.2M
Q3 25
$582.2M
$165.5M
Q2 25
$533.6M
$116.4M
Q1 25
$559.4M
$112.2M
Q4 24
$604.3M
$111.3M
Q3 24
$675.6M
$131.4M
Q2 24
$279.4M
$74.9M
Q1 24
$345.9M
$71.8M
Stockholders' Equity
ASND
ASND
SSTK
SSTK
Q4 25
$-175.8M
$581.0M
Q3 25
$-188.0M
$594.4M
Q2 25
$-202.6M
$586.2M
Q1 25
$-205.0M
$547.2M
Q4 24
$-114.2M
$518.4M
Q3 24
$-105.1M
$522.9M
Q2 24
$-346.8M
$520.4M
Q1 24
$-257.2M
$541.3M
Total Assets
ASND
ASND
SSTK
SSTK
Q4 25
$1.4B
$1.4B
Q3 25
$1.2B
$1.4B
Q2 25
$1.2B
$1.4B
Q1 25
$1.1B
$1.3B
Q4 24
$1.3B
$1.3B
Q3 24
$1.2B
$1.3B
Q2 24
$819.0M
$1.0B
Q1 24
$866.7M
$1.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASND
ASND
SSTK
SSTK
Operating Cash FlowLast quarter
$58.2M
$36.2M
Free Cash FlowOCF − Capex
$25.9M
FCF MarginFCF / Revenue
11.8%
Capex IntensityCapex / Revenue
4.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$123.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASND
ASND
SSTK
SSTK
Q4 25
$58.2M
$36.2M
Q3 25
$78.4M
Q2 25
$26.8M
Q1 25
$-15.5M
$25.2M
Q4 24
$-330.7M
$8.0M
Q3 24
$-11.6M
Q2 24
$28.0M
Q1 24
$-109.7M
$8.3M
Free Cash Flow
ASND
ASND
SSTK
SSTK
Q4 25
$25.9M
Q3 25
$68.0M
Q2 25
$15.5M
Q1 25
$14.4M
Q4 24
$-952.0K
Q3 24
$-26.3M
Q2 24
$18.9M
Q1 24
$-6.2M
FCF Margin
ASND
ASND
SSTK
SSTK
Q4 25
11.8%
Q3 25
26.1%
Q2 25
5.8%
Q1 25
6.0%
Q4 24
-0.4%
Q3 24
-10.5%
Q2 24
8.6%
Q1 24
-2.9%
Capex Intensity
ASND
ASND
SSTK
SSTK
Q4 25
4.7%
Q3 25
4.0%
Q2 25
4.2%
Q1 25
4.5%
Q4 24
3.6%
Q3 24
5.9%
Q2 24
4.1%
Q1 24
6.7%
Cash Conversion
ASND
ASND
SSTK
SSTK
Q4 25
Q3 25
5.86×
Q2 25
0.91×
Q1 25
1.35×
Q4 24
Q3 24
-0.66×
Q2 24
7.71×
Q1 24
0.51×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons